Jena, 27.04.2026. A significant milestone in German and international medical research is imminent: A novel antibiotic against tuberculosis developed in Jena has reached the phase of final, decisive tests.
- What: Development of a new antibiotic against tuberculosis
- Who: Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie
- Where: Jena
- Special feature: First new antibiotic from Germany in 50 years
Hope in the Fight Against Tuberculosis
The search for and research into new active substances against bacterial infections has long been difficult worldwide. Now there is a massive scientific success from Thüringen: For the first time in half a century, a new antibiotic is expected to come from Germany again. The drug, which was specifically designed for the treatment of tuberculosis, is currently undergoing final test series. If these are successful, the agent could soon be used worldwide to save human lives.
Background: Research at Beutenberg and the Disease Tuberculosis
The responsible Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie (HKI) focuses its research on the infection biology of human-pathogenic fungi and bacteria. It is based at the Beutenberg Campus in Jena, which is considered a significant center for optics, photonics, health, and biotechnology in Europe. Tuberculosis is a bacterial infectious disease that usually affects the lungs. According to the World Health Organization (WHO), it remains one of the world’s most dangerous and deadliest infectious diseases. A massive problem in modern medicine is that tuberculosis pathogens are increasingly developing resistance to previously common antibiotics. The new development from Jena therefore comes at a critical time in the global fight against multi-resistant germs.
Source:
New antibiotic from Jena before final tests | MDR.DE
Transparency note: This article was automatically created, editorially reviewed, and expanded with AI support.